Study of PX-866 and Docetaxel in Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

223

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

December 31, 2013

Study Completion Date

February 28, 2014

Conditions
Non Small Cell Lung Cancer (NSCLC)Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions
DRUG

Docetaxel

DRUG

PX-866

Trial Locations (33)

10003

Beth Israel Hospital, New York

10016

New York University Medical Center, New York

10032

Columbia University Medical Center, New York

10467

Montefiore Medical Center, The Bronx

12110

New York Oncology, Hematology, Latham

14263

Roswell Park Cancer Institute, Buffalo

15232

University of Pittsburgh Medical Center, Pittsburgh

19104

University of Pennsylvania, Philadelphia

21231

John Hopkins University, Baltimore

22031

Virginia Cancer Specialists, Fairfax

23606

Virginia Oncology Associates, Newport News

24073

Oncology and Hematology Associates of SW Virginia, DBA Blue Ridge Cancer Care, Christiansburg

29425

Medical University of South Carolina, Charleston

34619

Cancer Center of Pasco-Pinellas, Holiday

35294

University of Alabama at Birmingham, Birmingham

63110

Washington University, St Louis

67214

Cancer Center of Kansas, Wichita

75201

Mary Crowley Cancer Center, Dallas

75246

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas

78745

Texas Oncology - South Austin, Austin

80045

University of Colorado Cancer Center, Aurora

80220

Eastern Colorado Health Care System - Denver VA, Denver

87131

New Mexico Cancer Care Alliance, Albuquerque

92025

Southwest Cancer Care, Escondido

94523

Bay Area Cancer Research Group, LLC, Pleasant Hill

97062

Northwest Cancer Specialists, Tualatin

98902

Yakima Valley Memorial Hospital/North Star Lodge, Yakima

99208

Medical Oncology Associates, Spokane

99336

Columbia Basin Hematology & Oncology, Kennewick

R3E 0V9

Cancer Care Manitoba, Winnipeg

N6A 4L6

London Regional Cancer Program, London

H3T1E2

Jewish General Hospital, Montreal

J1H 5N4

CHUS Hopital Fleurimont, Sherbrooke

Sponsors
All Listed Sponsors
lead

Cascadian Therapeutics Inc.

INDUSTRY

NCT01204099 - Study of PX-866 and Docetaxel in Solid Tumors | Biotech Hunter | Biotech Hunter